ClinicalTrials.gg
RecruitingNCT04221542Updated Nov 12, 2026

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of AMG 509 and Abiraterone in Prostate Cancer, sponsored by Amgen. Recruiting at 54 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2020; still recruiting 6 years 8 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Planned enrollment
6th of 21
505 · median 64
Started
2020
the only one that year
Phase 1
9 of 23
3 open now
Registered
15th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 9 in phase 1, and was the 15th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10.2 (31 Aug 2026), only Parts 6 and 7 are open to accrual.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • AMG 509
  • mCRPC
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate cancer
  • PSMA
  • STEAP1
  • STEAP1 targeted therapy
  • Solid tumor
  • Immunotherapy
  • Immuno-oncology
  • Immunooncology
  • Bispecific T-Cell engager®
  • BiTE®
  • XmAb®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Parts 1, 2, 5 and 7: Participants with or cytologically confirmed castration-resistant prostate cancer (mCRPC) who are to a novel antiandrogen therapy (abiraterone acetate and/or enzalutamide, apalutamide, or darolutamide) and have failed at least 1 (but not more than 2) taxane regimens including for metastatic hormone-sensitive prostate cancer (mHSPC) (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen). Note: A taxane regimen is defined as a minimum exposure of 2 cycles of a taxane. Any NHT that has been administered and has been stopped for reasons other than progression will not be counted as an additional .

    1. Dose exploration phase: Novel antiandrogen therapy must have been given for treatment of metastatic disease.
    2. Dose-expansion phase: participants must not have had more than 2 NHTs and 2 taxane regimens in any setting, and an additional up to 2 other systemic anti-cancer treatments are allowed (eg, anti-PD1, PARP inhibitors, radioligand therapies, sipuleucel-T, experimental agents) Note: Combinations are considered one systemic anti-cancer treatment.
  • Part 3: Participants with histologically or cytologically confirmed mCRPC who have received no or 1-2 prior NHTs (abiraterone acetate, enzalutamide, apalutamide, or darolutamide) given in any disease setting and who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen (unless taxane treatment was administered in HSPC setting). 0 1 prior PARP inhibitors or sipuleucel-T treatments are acceptable. Participants who received prior therapy for the treatment of metastatic disease are not eligible.
  • Parts 4A, 4B and 7:

    1. Participants with histologically or cytologically confirmed mCRPC who have received no or 1-2 prior NHTs (given in any disease setting depending on the part), and no or 1 taxane regimen (for HSPC).
    2. Dose-expansion phase: at least 1 prior NHT must have been given; 0-1 prior PARP inhibitors are acceptable.
    3. 4A: Participants planning to receive abiraterone acetate for the first time (participants who received prior abiraterone acetate are not eligible). Participants may have had exposure to up to 2 NHTs with a similar mechanism of action (apalutamide, enzalutamide or darolutamide) in the non-mCRPC and mCRPC setting.
  • Dose-expansion phase: up to approximately 10 participants with prior exposure to abiraterone acetate may be enrolled into Part 4A expansion cohort.

    d. 4B: Participants planning to receive enzalutamide for the first time (participants who received prior enzalutamide/apalutamide or daralutamide are not eligible).

  • Part 6:

    1. Prior disease progression on 1, and only 1, NHT (either enzalutamide, apalutamide, or darolutamide) is required. NOTE: Prior progression on or intolerance to abiraterone is not allowed.
    2. No prior treatment with any chemotherapy regimen in the mCRPC setting; ≤ 6 cycles of docetaxel treatment in the mHSPC setting is allowed.
    3. mCRPC with ≥ 1 v1.1 that is present on baseline computed tomography (CT) or magnetic resonance imaging (MRI).
  • All parts:
  • Participants must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a gonadotropin releasing hormone (GnRH) agonist or antagonist.
  • Total serum testosterone ≤ 50 ng/dL or 1.7 nmol/L.
  • Evidence of progressive disease, defined as 1 or more Prostate Cancer Working Group 3 (PCWG3) criteria:

    1. PSA level ≥ 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart.
    2. Nodal or visceral progression as defined by RECIST v1.1 with PCGW3 modifications.
    3. Appearance of 2 or more new lesions in bone scan.
  • performance status of 0-1.
  • ≥ 3 months.
  • Adequate organ function, defined as follows:

    1. Hematological function:

      1. ≥ 1 x 10\^9/L (without growth factor support within 7 days from screening assessment).
      2. count ≥ 75 x 10\^9/L (without platelet transfusion within 7 days from screening assessment).
      3. ≥ 9 g/dL (90 g/L) (without blood transfusion within 7 days from screening assessment).
    2. Renal function:

      1. estimated based on Modification of Diet in Renal Disease calculation ≥ 30 ml/min/1.73 m\^2.

    3. Hepatic function:

      1. (AST) and alanine aminotransferase (ALT) \< 3 x (ULN) (or \< 5 x ULN for participants with liver involvement).
      2. total (TBL) \< 1.5 x ULN (or \< 2 x ULN for participants with liver metastases).
    4. Cardiac function:

      1. > 50% (2-D transthoracic echocardiogram [ECHO] is the preferred method of evaluation; multi-gated acquisition scan is acceptable if ECHO is not available).
      2. Baseline (ECG) ≤ 470 msec (average of triplicate values).
    5. Pulmonary function:

      1. baseline oxygen saturation > 92% on room air at rest and no oxygen supplementation.

Part 3-Retreatment group:

  • Deriving benefit from initial treatment with AMG 509 as evidenced by one of the following:

    1. confirmed PSA50 response.
    2. radiographic stable disease/partial response/complete response during 6 cycles of initial treatment with AMG 509 and without progression during the first 6 cycles.
  • No discontinuation for toxicity during the initial treatment with 6 cycles of AMG 509.
  • Progressive disease as defined in I106 within 12 months of final dose in their initial treatment with 6 cycles (EOT_1).
  • Willingness to have a fresh tumor prior to initiating the additional course of treatment, depending on safety and feasibility as assessed by investigator.

Key Exclusion Criteria:

  • Pathological finding consistent with pure small cell, neuroendocrine carcinoma of the prostate or any other histology different from adenocarcinoma.
  • Radiation therapy within 4 weeks of first dose (or local or focal radiotherapy within 2 weeks of first dose).
  • Untreated central nervous system (CNS) metastases or . Participants with a history of treated are eligible if there is radiographic evidence of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study.
  • Prior major surgery within 4 weeks of first dose.
  • Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of investigational product administration. Simple urinary tract infections and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with sponsor. Screening for chronic infectious conditions is not required.
  • Confirmed history or current disease or other diseases resulting in permanent or requiring permanent immunosuppressive therapy.
  • History of arterial or venous thrombosis (eg, stroke, , pulmonary embolism, or deep vein thrombosis); for arterial thrombosis within 12 months of AMG 509 initiation; for venous thrombosis, 6 months and stable on anti-coagulation. Participants with a recent history of venous thrombosis must be maintained on the same anti-coagulation therapy for a minimum of 28 days prior to first dose of study treatment.
  • Myocardial infarction and/or symptomatic congestive heart failure ( > class II) within 12 months of first dose of AMG 509 with the exception of ischemia or non-ST segment elevation myocardial infarction controlled with stent placement and confirmed by a cardiologist more than 6 months prior to first dose of AMG 509.
  • Any anti-cancer therapy or immunotherapy within 4 weeks of start of first dose, not including luteinizing hormone-releasing hormone (LHRH)/GnRH analogue (agonist/antagonist).
  • Prior prostate specific membrane antigen (PSMA) radionuclide therapy within 2 months prior to AMG 509 unless participant received \< 2 cycles (Note: a participant cannot have received PSMA radionuclide therapy \< 35 days prior to enrollment if 1 cycle was given). Parts 3 and 4: prior PSMA radionuclide therapy is prohibited. Participants on a stable bisphosphonate or denosumab regimen for ≥ 30 days prior to enrollment are eligible (exception: part 3 retreatment).
  • Part 3-Retreatment only: Any anti-cancer therapy or immunotherapy, not including luteinizing hormone-releasing hormone/gonadotropin releasing hormone (LHRH/GnRH) analogue (agonist/antagonist), and/or bisphosphonate or denosumab regimen after last dose of AMG 509 initial course of treatment.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
505 participants (estimated)

Study arms

  • Experimental
    Part 1: AMG 509 Intravenous (IV) Monotherapy

    Participants with metastatic castration-resistant prostate cancer (mCRPC) receive AMG 509 (xaluritamig) by short-term IV infusion.

    Drug: AMG 509

  • Experimental
    Part 2: AMG 509 Subcutaneous (SC) Monotherapy

    Participants with mCRPC receive AMG 509 by SC injection.

    Drug: AMG 509

  • Experimental
    Part 3: AMG 509 IV Monotherapy in Earlier Lines of Treatment

    Participants with mCRPC receive AMG 509 by IV infusion.

    Drug: AMG 509

  • Experimental
    Part 4: AMG 509 IV Combination Therapy

    Participants with mCRPC receive AMG 509 by IV infusion with either oral abiraterone acetate (Part 4A), or oral enzalutamide (Part 4B).

    Drug: AMG 509 · Drug: Abiraterone · Drug: Enzalutamide

  • Experimental
    Part 5: AMG 509 IV Monotherapy in Outpatient Setting

    Participants with mCRPC receive AMG 509 by IV infusion in an outpatient infusion setting.

    Drug: AMG 509

  • Experimental
    Part 6: AMG 509 IV as Monotherapy and Combination Therapy With Abiraterone Acetate

    Participants with mCRPC and measurable disease are randomized 1:1 to receive either AMG 509 by IV infusion or AMG 509 with oral abiraterone acetate.

    Drug: AMG 509 · Drug: Abiraterone

  • Experimental
    Part 7 (China only): AMG 509 IV as Monotherapy or in Combination With Abiraterone Acetate

    Participants in China receive AMG 509 by IV infusion as monotherapy or, if the combination cohort is initiated, with oral abiraterone acetate.

    Drug: AMG 509 · Drug: Abiraterone

Interventions

  • AMG 509 administered as an IV infusion (Parts 1, 3, 4, 5, 6 and 7) or SC injection (Part 2).

    Also known as: xaluritamig

  • Abiraterone administered as oral tablets.

  • Enzalutamide administered as oral tablets.

06

What researchers measure

Primary outcomes

  1. Parts 1-5 and 7: Incidence of Treatment-emergent Adverse Events

    Time frame: 3 years

  2. Parts 1-5 and 7: Incidence of Treatment-related Adverse Events

    Time frame: 3 years

  3. Parts 1-5 and 7 Dose Exploration Cohorts Only: Dose Limiting Toxicities (DLTs)

    Time frame: 28 days

  4. Parts 1-5 and 7: Number of Participants with Changes in Vital Signs

    Time frame: 3 years

  5. Parts 1-5 and 7: Number of Participants with Changes in Electrocardiogram (ECG) Records

    Time frame: 3 years

  6. Parts 1-5 and 7: Number of Participants with Changes in Clinical Laboratory Test Results

    Time frame: 3 years

  7. Part 6: Objective Response (OR) per RECIST v1.1

    Time frame: 3 years

Secondary outcomes

  1. Parts 1-7: Maximum Serum Concentration (Cmax) for AMG 509

    To characterize the pharmacokinetics (PK) of AMG 509

    Time frame: 3 years

  2. Parts 1-7: Time to Maximum Serum Concentration (Tmax) for AMG 509

    To characterize the pharmacokinetics (PK) of AMG 509

    Time frame: 3 years

  3. Parts 1-7: Minimum Serum Concentration (Cmin) for AMG 509

    To characterize the pharmacokinetics (PK) of AMG 509

    Time frame: 3 years

  4. Parts 1-7: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval for AMG 509

    To characterize the pharmacokinetics (PK) of AMG 509

    Time frame: 3 years

  5. Parts 1-7: Accumulation Following Multiple Dosing for AMG 509

    To characterize the pharmacokinetics (PK) of AMG 509

    Time frame: 3 years

  6. Parts 1-5 and 7: OR per RECIST v1.1

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  7. Parts 1-7: Prostate Specific Antigen (PSA) Response

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  8. Parts 1-5 and 7: PSA Decline of at Least 50% From Baseline at 12 Weeks

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: Week 12

  9. Parts 1-7: Radiographic Duration of Response (DOR)

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  10. Parts 1-5 and 7: PSA DOR

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  11. Parts 1-5 and 7: Radiographic Time to Progression

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  12. Parts 1-5 and 7: PSA Time to Progression

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  13. Parts 1-5 and 7: Radiographic Progression-free Survival (PFS)

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  14. Parts 1-5 and 7: PSA PFS

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  15. Part 6: Radiographic PFS per Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  16. Parts 1-2, 5 and 7: 6 Month Radiographic PFS

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 6 months

  17. Part 3 and 4: 1, 2, and 3-year Radiographic PFS

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: Year 1, 2, and 3

  18. Parts 1-5: 1, 2, and 3-year Overall Survival (OS)

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: Year 1, 2, and 3

  19. Parts 1-5: Circulating Tumor Cells Response (CTC0)

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  20. Parts 1-5: Rate of Circulating Tumor Cells (CTC) Conversion

    To evaluate preliminary anti-tumor activity of AMG 509

    Time frame: 3 years

  21. Parts 1-5: Time to Symptomatic Skeletal Events

    To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints.

    Time frame: 3 years

  22. Parts 1-5: Alkaline Phosphatase (Total, Bone)

    To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints.

    Time frame: 3 years

  23. Parts 1-5: Lactate Dehydrogenase (LDH)

    To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints.

    Time frame: 3 years

  24. Parts 1-5: Hemoglobin

    To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints.

    Time frame: 3 years

  25. Parts 1-5: Urine N-telopeptide

    To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints.

    Time frame: 3 years

  26. Parts 1-5: Neutrophil-to-lymphocyte Ratio

    To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints.

    Time frame: 3 years

  27. Part 6: Incidence of Treatment-emergent Adverse Events

    Time frame: 3 years

  28. Part 6: Incidence of Treatment-related Adverse Events

    Time frame: 3 years

  29. Part 6: Number of Participants with Changes in Vital Signs

    Time frame: 3 years

  30. Part 6: Number of Participants with Changes in Clinical Laboratory Test Results

    Time frame: 3 years

  31. Part 6: Disease Control per RECIST v1.1

    Time frame: 3 years

  32. Parts 6 and 7: OS

    Time frame: 3 years

07

Study locations

50 of 54 sites recruiting
08

References and documents

Publications

  • Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964. PubMed 37861461 ↗
  • Kuipers-Connarn JN, Pourzanjani A, Bose M, Modi S, Stieglmaier J, Murphy A, Mehta K, Upreti VV. Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb(R) 2+1 T-Cell Engager, in Prostate Cancer Patients. J Clin Pharmacol. 2025 Dec;65(12):1676-1686. doi: 10.1002/jcph.70074. Epub 2025 Aug 5. PubMed 40765197 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Jul 2030, 124 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 124 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2030 → Jul 2030 and completion Mar 2032 → Jul 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2019
First posted
Jan 9, 2020
StartActual
Mar 4, 2020
Primary completionEst.
Jul 28, 2030was Mar 2030
CompletionEst.
Jul 29, 2032was Mar 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 10 sites removed
Show 7 added (6 United States, 1 China)
  • Rocky Mountain Cancer Centers · Denver, United States
  • Tulane Medical Center · Rochester, United States
  • MidAmerica Cancer Care · Kansas City, United States
  • Yale New Haven Hospital · New York, United States
  • Duke University Medical Center Duke Cancer Center · Durham, United States
  • Virginia Oncology Associates · Irving, United States
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
Show 10 removed
  • Rocky Mountain Cancer Centers · Aurora, United States
  • Yale New Haven Hospital · New Haven, United States
  • MidAmerica Cancer Care · Merriam, United States
  • Tulane Medical Center · New Orleans, United States
  • Duke University Medical Center · Durham, United States
  • United States Oncology Regulatory Affairs Corporate Office · Nashville, United States
  • US Oncology Research Investigational Products Center · Irving, United States
  • Virginia Oncology Associates · Norfolk, United States
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
  • Kantonsspital Graubuenden · Chur, Switzerland
Nov 12, 2026
Primary completion
Mar 22, 2030→Jul 28, 2030
Nov 12, 2026
Study completion
Mar 21, 2032→Jul 29, 2032
Nov 12, 2026
Enrollment
479→505
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    7 sites added, 10 sites removed
    Show 7 added (6 United States, 1 China)
    • Rocky Mountain Cancer Centers · Denver, United States
    • Tulane Medical Center · Rochester, United States
    • MidAmerica Cancer Care · Kansas City, United States
    • Yale New Haven Hospital · New York, United States
    • Duke University Medical Center Duke Cancer Center · Durham, United States
    • Virginia Oncology Associates · Irving, United States
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    Show 10 removed
    • Rocky Mountain Cancer Centers · Aurora, United States
    • Yale New Haven Hospital · New Haven, United States
    • MidAmerica Cancer Care · Merriam, United States
    • Tulane Medical Center · New Orleans, United States
    • Duke University Medical Center · Durham, United States
    • United States Oncology Regulatory Affairs Corporate Office · Nashville, United States
    • US Oncology Research Investigational Products Center · Irving, United States
    • Virginia Oncology Associates · Norfolk, United States
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    • Kantonsspital Graubuenden · Chur, Switzerland
    Primary completion Mar 22, 2030→Jul 28, 2030
    Study completion Mar 21, 2032→Jul 29, 2032
    Enrollment 479→505
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04221542
Lead sponsor
Amgen
Collaborators
BeiGene, BeOne (China only)
Responsible party
Sponsor
First posted
Jan 9, 2020
Start date
Mar 4, 2020
Primary completion
Jul 28, 2030 (estimated)
Completion
Jul 29, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xaluritamig

Start the discussion